CAS 1239358-85-0

NS-018 (hydrochloride)

Description:

NS-018 (hydrochloride) is a synthetic compound that belongs to the class of substances known as cannabinoids. It is primarily studied for its potential effects on the endocannabinoid system, which plays a crucial role in various physiological processes. As a hydrochloride salt, NS-018 is typically more soluble in water compared to its free base form, which can enhance its bioavailability for research purposes. The compound is characterized by its selective action on cannabinoid receptors, particularly CB1 and CB2, which may influence appetite, pain perception, and mood regulation. Due to its relatively recent emergence in research, detailed pharmacological profiles and safety data are still being investigated. As with many synthetic cannabinoids, there may be concerns regarding its legal status, potential for abuse, and long-term effects on health. Researchers are encouraged to approach studies involving NS-018 with caution, adhering to ethical guidelines and regulatory requirements.

Formula: C₂₁H₂₁ClFN₇

Synonyms:

• NS-018 (hydrochloride)
• ILGINATINIB HYDROCHLORIDE (NS-018 HYDROCHLORIDE)
• Ilginatinib hydrochloride
• Tyk2,Ilginatinib,JAK1,JAK,JAK2,Inhibitor,bioavailable,NS018,NS-018,orally,inhibit,Janus kinase,JAK3,Ilginatinib hydrochloride,NS 018

Ilginatinib hydrochloride

CAS: 1239358-85-0

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.

Formula: C₂₁H₂₁ClFN₇

Purity: 99.55%

Color and Shape: Solid

Molecular weight: 425.89

Ref: TM-T12266L2

Ilginatinib hydrochloride

CAS: 1239358-85-0

Ilginatinib hydrochloride

Purity: ≥95%

Molecular weight: 425.89g/mol

Ref: 54-BUP08446

Ilginatinib hydrochloride

CAS: 1239358-85-0

Ilginatinib hydrochloride is a tyrosine kinase inhibitor that belongs to the group of targeted therapies. It blocks the activity of JAK2 (Janus kinase 2), which is associated with various types of cancers including myeloproliferative disorders and leukemia. Ilginatinib hydrochloride has been shown to be effective in the treatment of patients with chronic myelogenous leukemia who have a JAK2 V617F mutation. This drug also inhibits the growth factor signaling pathways, which leads to inhibition of cellular proliferation, differentiation, and survival. Symptoms may include fatigue, fever, weight loss, anemia, or infection. The molecular modeling study revealed that ilginatinib hydrochloride binds to the ATP-binding pocket in JAK2 V617F by forming hydrogen bonds with amino acid residues in this region.

Formula: C₂₁H₂₁ClFN₇

Purity: Min. 95%

Molecular weight: 425.89 g/mol

Ref: 3D-PZB35885